Page last updated: 2024-10-27

fluorouracil and Prostatic Neoplasms

fluorouracil has been researched along with Prostatic Neoplasms in 280 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Prostatic Neoplasms: Tumors or cancer of the PROSTATE.

Research Excerpts

ExcerptRelevanceReference
"The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile."9.11Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004)
"Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer."9.11Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005)
"One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i."9.07Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992)
"Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)."7.66Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983)
"Synergy was also achieved in the T24 bladder cancer line."5.31Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. ( Kamoi, K; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O, 2002)
"The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile."5.11Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004)
"Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer."5.11Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005)
"One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i."5.07Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992)
"This prospective randomized study in nonhormonally responsive adenocarcinoma of the prostate shows that response rates to melphalan vs cyclophosphamide groups were virtually identical."5.06Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. ( Berry, WR; Cox, EB; Graham, SD; Laszlo, J; Paulson, DF; Walker, A, 1986)
"In patients with metastatic hormone-relapsed adenocarcinoma of the prostate, adriamycin was compared to 5-fluorouracil in a randomized trial in 99 patients and adriamycin alone was studied in an open trial in 48 patients."5.05A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. ( Begg, CB; Brodovsky, H; Creech, R; DeWys, WD; Khandekar, J, 1983)
"In a prospective, randomized study the effect of cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy was compared to the single agent, chloroethyl-cyclohexy-nitrosourea, in the treatment of hormonally refractive metastatic prostatic carcinoma."5.05Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. ( Herr, HW, 1982)
"This National Cooperative Study has randomly compared the usefulness of 5-fluorouracil (5-FU), cyclophosphamide (Cytoxan) and standard therapy in patients with advanced carcinoma of the prostate (Stage D)."5.04Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy. ( Gibbons, RP; Johnson, DE; Murphy, GP; Prout, GR; Schmidt, JD; Scott, WW, 1976)
"Twenty-seven patients with a diagnosis of metastatic adenocarcinoma of the prostate were treated in a randomized, prospective trial with either Cyclophosphamide or a combination of Adriamycin, 5-Fluorouracil, and Cyclophosphamide."5.04Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. ( Bateman, JR; Chlebowski, RT; Hestorff, R; Sardoff, L; Weiner, J, 1978)
"The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy."3.75Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984)
"Human prostate cancer PC-3 and LnCaP, and human breast cancer MDA-468 cells and xenografts were treated with chemotherapy (docetaxel and 5-fluorouracil, respectively) and temsirolimus, using concurrent and sequential treatment schedules."3.75Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. ( Fung, AS; Tannock, IF; Wu, L, 2009)
"In all patients with advanced colorectal cancer, disease eventually progresses following fluorouracil (5-FU) therapy, with a worsening of disease-related symptoms and quality of life (QOL)."3.70Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. ( Michael, M; Moore, MJ, 1998)
"Based upon prior data suggesting that alpha-interferon possesses chemomodulatory activity, the Southwest Oncology Group conducted a study in which patients with hormone refractory, metastatic (stage D2) adenocarcinoma of the prostate were treated with 5-fluorouracil (5-FU) and Roferon-A."3.69Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. ( Barnett, TC; Crawford, ED; Marshall, ME; O'Rourke, M; Wolf, M, 1996)
"We evaluated conventional pulse exposure versus continuous exposure models of 5-fluorouracil (5-FU) radiosensitization in HT-29 (human colon adenocarcinoma) and DU-145 (human prostate cancer adenocarcinoma) cell lines."3.685-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. ( Evans, RG; Kimler, BF; Smalley, SR, 1991)
"Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil."3.67[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987)
"Twelve patients with stage D2 adenocarcinoma of the prostate were treated with the combination chemotherapy of ifosfamide (2 g/body, i."3.67[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. ( Andoh, M; Fukui, I; Higashi, Y; Horiuchi, S; Kihara, K; Kitahara, S; Oshima, H; Takeuchi, S, 1989)
"Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate."3.66[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983)
"Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)."3.66Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983)
"Twenty-five patients with histologically proved adenocarcinoma of the prostate were divided into two groups and submitted to combination therapy with estramustine (Estracyt), cyclophosphamide (Cytoxan), 5-fluorouracil, and Cisplatin."3.66Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. ( Beckley, S; Maeso, E; Murphy, G; Pontes, E; Wajsman, Z, 1981)
"Twenty-four patients with confirmed Stage D carcinoma of the prostate were treated with a combination of bilateral orchiectomy, estrogens (diethylstilbestrol) and chemotherapy (5-fluorouracil), and cyclophosphamide soon after diagnosis was established."3.66Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. ( Lurie, H; Mukamel, E; Nissenkorn, I; Servadio, C, 1983)
"A number of chemotherapeutic agents, including L-asparaginase, actinomycin D, chloroethylcyclohexy-nitrosourea, 5-flourouracil, cyclophosphamide, hydroxyurea, cis-platinum, adriamycin and methotrexate, alone and in combination and at variable dose levels, were applied against the Dunning R3327 rat prostatic adenocarcinoma-subline G."3.66Further experience with chemotherapy in the Dunning prostatic adenocarcinoma. ( Block, NL; Camuzzi, F; Claflin, A; Politano, VA; Stover, B; Troner, M, 1978)
"Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy."3.66Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. ( Ikard, M; Shippel, RM; Soloway, MS, 1979)
"Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate."3.65Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975)
" The primary end-point was to establish the maximum tolerable dose (MTD) of capecitabine when combined with (188)Re-HEDP."2.74(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. ( Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009)
"Capecitabine has limited activity as a single agent in prostate cancer, but appears to modulate tumour biology."2.71Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. ( Bolunwu, N; Chan, S; Kendall, A; Pandha, H; Plunkett, T; Somaiah, N; Spicer, J, 2005)
"Then, 23 cases of local relapsed prostate cancer and two cases of endpocrine-resistant prostate cancer were administered the chemotherapy."2.69[Intra-arterial chemotherapy via reservoir system for advanced bladder cancer and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1999)
"5-Fluorouracil has been reported to have modest antitumor activity in androgen independent prostate cancer."2.68The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. ( Daliani, DD; Eisenberg, PD; Fueger, R; Logothetis, CJ; Lord, R; Weems, J, 1995)
"Hormone-refractory metastatic prostate cancer remains a disease for were limited therapeutic options are available."2.68[5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer]. ( Demura, T; Harabayashi, T; Koyanagi, T; Matsuda, H; Matsumara, K; Nagomori, S; Nonomura, K; Nounaka, O; Ohmuro, H; Shinohara, N, 1995)
"In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions."2.68A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. ( Chao, D; Harland, SJ; von Schlippe, M, 1997)
"5-fluorouracil (5-FU) is a known radiosensitizer that enhances efficacy, in vivo and in vitro, when administered during radiotherapy."2.68Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. ( Dreicer, R; Forest, PK; Loening, S; See, WA; Wheeler, JA, 1996)
"2 per day) combined with a fixed dose of interferon-alpha 2b (5 million units) and allopurinol (300 mg."2.685-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. ( Amdur, RJ; Ernstoff, MS; Fukui, I; Glazier, DB; Harris, R; Heaney, JA; Schned, AR, 1996)
" 5FU was given as a 24-hour infusion at a dosage of 4 g/m2 and oral leucovorin at a dosage of 50 mg every 6 hours for four doses, starting with the infusion of 5FU."2.68Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. ( Atkins, JN; Case, LD; Grote, T; McFarland, J; Muss, HB; Richards, F, 1996)
" Patients were treated with 5-fluorouracil given at a dosage of 4 gm/m2 over a 24-hour period every 2 weeks."2.67High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. ( Anthony, S; Atkins, JN; Brockschmidt, J; Case, D; Grote, TH; Muss, HB; O'Rourke, M; Schnell, FM; Stanley, V; West, JH, 1991)
" Frequent dosage modifications were required with the dose intensity of 5-FU and alpha interferon of 57% and 58%, respectively."2.67Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. ( Dreicer, R; Forest, PK; Williams, RD, 1994)
"5-Fluorouracil (5-FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer."2.67A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. ( Benson, AB; Blough, R; Braud, E; Johnson, P; Kilton, L; Kozlowski, J; Kuzel, TM; Shevrin, D; Tallman, MS; Vogelzang, NJ, 1993)
"Hormone-refractory metastatic prostate cancer remains a therapeutic challenge."2.67Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. ( Blumenstein, BA; Boileau, M; Crawford, ED; Fletcher, WS; Rivkin, SE; Wozniak, AJ, 1993)
"Twenty patients with metastatic prostatic cancer were treated on an ambulatory basis with continuous 5-fluorouracil (5-FU) infusion 250-300 mg/M2 per day through a chronic indwelling central venous catheter."2.67Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. ( Anderson, T; Beatty, P; Hansen, R; Libnoch, J; Moynihan, T; Quebbeman, E; Schulte, W, 1991)
"Seventy-five patients with stage D-2 prostate cancer refractory to orchiectomy have been entered in a controlled trial to test whether androgen priming enhances the efficacy of chemotherapy."2.66Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer. ( Boucher, AE; Drago, J; Gordon, R; Harvey, H; Lipton, A; Manni, A; Rohner, T; Santen, RJ; Simmonds, M; Wettlaufer, J, 1987)
"Eighty-five men with progressive prostate cancer refractory to orchiectomy were treated continuously with aminoglutethimide and hydrocortisone to lower adrenal androgen secretion and were administered cyclic intravenous (IV) chemotherapy."2.66Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. ( Bartholomew, M; Boucher, A; Caplan, R; Gordon, R; Harvey, H; Lipton, A; Manni, A; Santen, R; Simmonds, M; White-Hershey, D, 1988)
" Future studies utilizing these or other agents, in similar or modified dosage schedules or delivery mechanisms, should note these results."2.66Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. ( Murphy, GP; Priore, RL; Scardino, PT, 1988)
"Although patients with metastatic prostatic cancer may benefit from chemotherapy, impressive clinical responses are uncommon."2.65Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. ( Brodkin, R; Cooper, MR; Howard, V; Jackson, DV; Muss, HB; Resnick, MI; Richards, F; Spurr, CL; Stuart, JJ; White, DR, 1981)
"The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg."2.65A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. ( Bartolucci, AA; Hemstreet, G; Hester, M; Smalley, RV, 1981)
" Effectiveness of 5-fluorouracil in combination with hormones (estrogen or gestagen) in low doses, as a basal treatment, was compared with that of hormones alone in high doses."2.65[Effectiveness of 5-fluorouracil combined with hormones in low dose as a basal treatment for prostatic carcinoma]. ( Takeuchi, H, 1984)
"The National Prostatic Cancer Project has randomized this study for endocrine-resistant prostatic cancer patients for treatment with standard hormonal or other therapies compared to 5-fluorouracil and cyclophosphamide."2.64Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. ( Gibbons, RP; Johnson, DE; Joiner, JR; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JE; Scott, WW, 1975)
" While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics."2.45Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. ( Halldén, G, 2009)
"The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria."2.37Chemotherapy principles in the treatment of prostatic cancer. ( Könyves, I; Müntzing, J; Rozencweig, M, 1984)
"Alopecia was observed in 60% of patients."1.62Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021)
" These results also validate that CLZ has significant anticancer activity both alone and in combination and support the strategy of drug repurposing coupled to drug combination for prostate cancer therapy."1.62Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines. ( Duarte, D; Vale, N, 2021)
"We report the case of an 84 years old prostate cancer patient with severe side effects after radiotherapy in 2006."1.39Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient-a case report. ( Eble, MJ; Kriehuber, R; Pinkawa, M; Schmitz, S, 2013)
"LNCaP cells, androgen dependent prostate cancer (ADPC) cells and C4-2 cells, which are a CRPC subline of LNCaP cells, were used."1.38Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer. ( Hasegawa, M; Ide, H; Kikuchi, E; Kosaka, T; Maeda, T; Miyajima, A; Oya, M; Shirotake, S; Tanaka, N; Yasumizu, Y, 2012)
"The risk of prostate cancer has been increasing in men by degrees."1.38Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells. ( Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR, 2012)
"HCT116 colorectal or PPC1 prostate cancer cells were treated with quercetin and the drugs."1.38Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. ( Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T, 2012)
"Among the panel of cancer cell lines, all studied polymeric FdU-conjugates demonstrated an up to 50× increased cytotoxicity in human prostate cancer PC-3, breast cancer MCF-7, and MDA-MB-231 cells, and more than 100× higher efficacy against cytarabine-resistant human T-lymphoma (CEM/araC/8) and gemcitabine-resistant follicular lymphoma (RL7/G) cells as compared to free drugs."1.37Novel anticancer polymeric conjugates of activated nucleoside analogues. ( Senanayake, TH; Vinogradov, SV; Warren, G, 2011)
"Some prostate and breast cancer cell lines highly expressed NCAM2 whereas normal prostate cell lines expressed NCAM2 at low levels."1.37Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy. ( Hamada, H; Kato, K; Kubota, K; Nakamura, K; Nakano, R; Takahashi, S, 2011)
" These results suggest that the up-regulation of IGFBP3 induced by 5-FU plays an important role in the potent anti-tumor effect of 5-FU combined with anti-androgens on CRPC."1.37Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. ( Itoh, K; Kanayama, H; Kawabata, R; Oie, S; Oka, T; Takahashi, M, 2011)
"Twenty men with primary rectal cancer clinically involving the lower urinary tract organs underwent extended colorectal resection combined with radical prostatectomy."1.36Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract. ( Ito, M; Kobayashi, A; Minagawa, N; Nishizawa, Y; Saito, N; Sugito, M; Suzuki, T; Tanaka, T; Watanabe, K, 2010)
"The various percentages of prostate cancer cells (LNCaP) transfected and non-transfected were mixed to observe the bystander effect of suicide gene system UPRT/5-FU."1.35[Bystander effect of target-regulated uracil phosphoribosyltransferase/5-fluorouracil suicide gene system on prostate cancer cell]. ( Li, H; Li, X; Wei, Q; Zeng, H; Zhao, FJ, 2008)
"Taking advantage of this prostate cancer-specific property of PSMA(E/P), we successfully introduced bacterial UPRT into LNCaP cells where the tumoricidal effect of 5-fluorouracil (5-FU) was significantly increased when compared with the cells without the exogenous UPRT."1.35Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. ( Li, H; Xia, SJ; Yu, ZM; Zhang, S; Zhao, FJ, 2009)
"Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)."1.35Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008)
"Although patients with metastatic prostate cancer can benefit from androgen ablation, most of them will die of prostate cancer progression to an androgen-refractory state."1.34Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. ( Hung, H, 2007)
"He was diagnosed as advanced sigmoid colon cancer which invaded the rectal colon (Ra) and prostate (SI, N 0, P 0, H 0, M (-), cStage IIIa)."1.34[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery]. ( Maezawa, K; Mizukami, H; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2007)
"We herein report on a case of pure squamous cell carcinoma of the prostate approached with combined-modality treatment, with the administration of 3 courses of cisplatin 75 mg/m(2) on day 1 and continuous infusion 5-fluorouracil 750 mg/m2 on day 1 to 5 and, subsequently, radiotherapy, with the delivery of a total dose of 46 Gy to the whole pelvis, with additional boost doses of 20 Gy to the prostatic bed and adjunctive 6 Gy to the prostate gland (72 Gy in total)."1.34Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. ( Ciammella, P; Clerico, M; Filippi, AR; Franco, P; Giudici, M; Munoz, F; Ricardi, U, 2007)
"In cultured human prostate cancer lines (DU145 and LNCaP), we compared the cytotoxicity of 5-FU/CDHP with that of 5-FU alone."1.34The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. ( Kawauchi, A; Li, Y; Mikami, K; Miki, T; Mizutani, Y; Nakamura, T; Okihara, K; Sakai, T; Shiraishi, T; Takaha, N, 2007)
"With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level."1.33Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005)
"Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis."1.33Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. ( Crawford, ED; Faulkner, J; Noble, MJ; O'Rourke, TJ; Quick, DP; Smalley, SR; Stephens, RL; Swanson, GP; Thompson, IM; Weiss, GR, 2006)
"Limitations of prostate cancer therapy may be overcome by combinations of chemotherapeutic agents with gene therapy directed against specific proteins critical for disease progression."1.33Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. ( Atweh, GF; Mistry, SJ, 2006)
" These can be enhanced with ultrasound imaging that depicts tumor margins; facilitates guidance, delivery, and dosage of local chemotherapy; and can monitor the effectiveness of the treatment."1.32Ultrasound guided combined cryoablation and microencapsulated 5-Fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging. ( Aller, A; Doulat, J; Haddad, RS; Le Pivert, P; Morrison, DR; Renard, M; Titus, K, 2004)
"Bioluminescent PC-3M-luc-C6 human prostate cancer cells were implanted subcutaneously into SCID-beige mice and were monitored for tumor growth and response to 5-FU and mitomycin C treatments."1.32Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. ( Contag, PR; Dusich, J; Hornig, YS; Jenkins, DE; Oei, Y; Purchio, T; Yu, SF, 2003)
"5-Fluorouracil is known to inhibit thymidylate synthase (TS), a key enzyme that transfers a methyl group from 5,10-methylene-tetrahydrofolate to dUMP during nucleotide biosynthesis."1.32Methionine restriction selectively targets thymidylate synthase in prostate cancer cells. ( Chen, GL; Epner, DE; Kwabi-Addo, B; Lu, S; Ren, C, 2003)
"A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West."1.31[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]. ( Aiba, K; Akaza, H; Blackledge, G; Hinotsu, S; Isonishi, S; Kono, S; Mikami, O; Noguchi, S; Ogawa, O; Shibuya, M; Sone, S; Stribling, D; Tsuruo, T; Vose, B, 2000)
"Two patients were diagnosed with large rectal tumors and localized prostate cancer."1.31External beam radiotherapy for synchronous rectal and prostatic tumors. ( Kapp, DS; King, C; Siu, W; Terris, MK; Wren, SM, 2001)
"A human prostate cancer cell (PC-3) model was exposed to 5-fluorouracil (5-FU) for 2 and 4 days (prefreeze), freezing (-5 to -100 degrees C), or a combination of the two treatments, and each was assessed for effectiveness over a 2-week posttreatment period."1.31Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. ( Baust, JG; Baust, JM; Clarke, DM; Van Buskirk, RG, 2001)
"Carmustine (BCNU) is an anticancer agent and a putative inhibitor of Gly-I, while beta-glucan is a unique, nontoxic polysaccharide extracted from maitake mushrooms."1.31Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. ( Aynehchi, S; Choudhury, MS; Drinis, S; Finkelstein, MP; Konno, S; Samadi, AA; Tazaki, H, 2002)
"LNCaP human prostate cancer cells were co-transfected with these 2 plasmids and luciferase activity was measured to assess promoter activities."1.31Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. ( Hayakawa, M; Ikegami, S; Suzuki, S; Tadakuma, T; Yoshimura, I, 2002)
"Synergy was also achieved in the T24 bladder cancer line."1.31Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. ( Kamoi, K; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O, 2002)
"Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy."1.30[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998)
"The protocol for renal cell carcinoma consisted of combined chemotherapy with continuous infusion of 5-FU 250 mg/m2/day and CDDP 3 mg/m2/day in 2 weeks for 1 cycles (4 weeks)."1.30[Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma]. ( Hata, M; Ono, S; Ota, N; Otsuka, A, 1997)
"Suramin has shown antitumour activity in vitro and in vivo."1.29The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994)
"Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated."1.28[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991)
" These data suggest that differentiation agents may provide additional antineoplastic benefits when administered in combination with selected chemotherapeutic agents in the management of prostatic cancer."1.28Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma. ( Carvalho, L; Foulkes, K; Mickey, DD, 1989)
"A human testicular cancer serially transplanted in nude mice was repeatedly exposed to CDDP in vivo to obtain hyposensitivity to this drug."1.27[Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro]. ( Hashimura, T; Hida, S; Kanamaru, H; Nishimura, K; Nishio, Y; Oishi, K; Okada, K; Yamauchi, T; Yoshida, O; Yoshiki, T, 1988)
"The 5-FU concentration of prostatic cancer was almost equal to that of normal prostatic tissue."1.27[Study on the concentration of FT-207 and 5-FU in serum and tissues of bladder tumor and prostatic carcinoma]. ( Kobayashi, H; Obata, K; Sahashi, M, 1986)
"Regional arterial infusion of high doses of anti-cancer drugs combined with direct hemoperfusion was done in 12 patients with malignancies of the urinary tract."1.26Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract. ( Harada, T; Nishizawa, O; Ohmura, H; Tsuchida, S, 1982)
"Hepatic hypoglycemia is discussed and the literature is reviewed."1.26Hypoglycemia secondary to metastases to the liver. A case report and review of the literature. ( Chawla, SK; LoPresti, PA; Sossi, AJ; Soterakis, J; Younus, S, 1977)
"A trial to reduce the dosage of estrogen or to substitute it by other agents was done as a treatment of prostatic carcinoma."1.26The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma. ( Takeuchi, H, 1981)
"The problems of defining response in prostatic cancer are discussed and a protocol for the future is outlined."1.26The non-hormone chemotherapy of prostatic cancer. ( Jones, MA; Williams, G, 1980)
"A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin."1.26Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981)
"Soft tissue metastases may be more responsive than bony lesions."1.26Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978)

Research

Studies (280)

TimeframeStudies, this research(%)All Research%
pre-1990125 (44.64)18.7374
1990's43 (15.36)18.2507
2000's67 (23.93)29.6817
2010's40 (14.29)24.3611
2020's5 (1.79)2.80

Authors

AuthorsStudies
Gududuru, V4
Hurh, E4
Durgam, GG1
Hong, SS1
Sardar, VM1
Xu, H1
Dalton, JT4
Miller, DD4
Sullivan, J1
Liu, XH1
Lv, PC1
Xue, JY1
Song, BA1
Zhu, HL1
Reddy, DM1
Qazi, NA1
Sawant, SD1
Bandey, AH1
Srinivas, J1
Shankar, M1
Singh, SK1
Verma, M1
Chashoo, G1
Saxena, A1
Mondhe, D1
Saxena, AK1
Sethi, VK1
Taneja, SC1
Qazi, GN1
Sampath Kumar, HM1
Riganas, S1
Papanastasiou, I1
Foscolos, GB1
Tsotinis, A1
Serin, G1
Mirjolet, JF1
Dimas, K1
Kourafalos, VN1
Eleutheriades, A1
Moutsos, VI1
Khan, H2
Georgakopoulou, S1
Zaniou, A1
Prassa, M1
Theodoropoulou, M1
Mantelas, A1
Pondiki, S1
Vamvakides, A1
Liu, GZ1
Xu, HW1
Wang, P1
Lin, ZT1
Duan, YC1
Zheng, JX1
Liu, HM1
Mochona, B1
Qi, X1
Euynni, S1
Sikazwi, D1
Mateeva, N1
Soliman, KF1
Sun, CP1
Qiu, CY1
Yuan, T1
Nie, XF1
Sun, HX1
Zhang, Q1
Li, HX1
Ding, LQ1
Zhao, F1
Chen, LX1
Qiu, F1
Mandalapu, D1
Saini, KS1
Gupta, S1
Sharma, V1
Yaseen Malik, M1
Chaturvedi, S1
Bala, V1
Thakur, S1
Maikhuri, JP1
Wahajuddin, M1
Konwar, R1
Gupta, G1
Sharma, VL1
Cao, Y1
Yang, Y3
Ampomah-Wireko, M1
Obaid Arhema Frejat, F1
Zhai, H1
Zhang, S2
Wang, H3
Yang, P1
Yuan, Q1
Wu, G1
Wu, C2
Dung, DTM1
Park, EJ1
Anh, DT1
Hai, PT1
Huy, LD1
Jun, HW1
Kwon, JH1
Young Ji, A1
Kang, JS1
Tung, TT1
Dung, PTP1
Han, SB1
Nam, NH1
Duarte, D1
Vale, N1
Salerno, L1
Sorrenti, V1
Pittalà, V1
Consoli, V1
Modica, MN1
Romeo, G1
Marrazzo, A1
Giuliano, M1
Zajdel, P1
Vanella, L1
Intagliata, S1
Fukui, K1
Nagasawa, S1
Hanasaki, T1
Ueda, Y1
Aihara, K1
Kokura, K1
Matsuo, S1
Zozumi, M1
Tsukamoto, Y1
Ben Nasr, S1
Zribi, A1
Ben Hassen, M1
Doghri, Y1
Ben Abdallah, I1
Trigui, E1
Fendri, S1
Ayari, J1
Balti, M1
Haddaoui, A1
Denslow, A1
Świtalska, M1
Jarosz, J1
Papiernik, D1
Porshneva, K1
Nowak, M1
Wietrzyk, J1
Schmitz, S1
Pinkawa, M1
Eble, MJ1
Kriehuber, R1
Dueregger, A1
Guggenberger, F1
Barthelmes, J1
Stecher, G1
Schuh, M1
Intelmann, D1
Abel, G1
Haunschild, J1
Klocker, H1
Ramoner, R1
Sampson, N1
Bazan, JG1
Luxton, G1
Kozak, MM1
Anderson, EM1
Hancock, SL1
Kapp, DS2
Kidd, EA1
Koong, AC1
Chang, DT1
Jin, P1
Xie, J1
Zhu, X3
Zhou, C1
Ding, X1
Yang, L1
Carmona, R1
Pritz, J1
Bydder, M1
Gulaya, S1
Zhu, H1
Williamson, CW1
Welch, CS1
Vaida, F1
Bydder, G1
Mell, LK1
Hajikarimi, Z1
Khoei, S1
Khoee, S1
Mahdavi, SR1
Yang, Q1
Li, L1
Sun, W1
Huang, Y2
Zhang, L1
Hoffman, RM2
Deng, Y1
Wang, J2
Zhao, FJ2
Li, H2
Zeng, H1
Wei, Q1
Li, X1
Yu, ZM1
Xia, SJ1
Tanaka, T4
Kawashima, H2
Matsumura, K2
Yamashita-Hosono, T1
Yoshimura, R1
Kuratsukuri, K2
Harimoto, K1
Nakatani, T3
Iguchi, T1
Uchida, J1
Nakamura, T2
Kawamura, M1
Wakasa, K1
Zheng, C1
Ren, Z1
Zhang, W1
Kalvakolanu, DV1
Tian, Z1
Xiao, W1
Lam, MG1
Bosma, TB1
van Rijk, PP1
Zonnenberg, BA1
Xing, L1
Sun, X1
Deng, X1
Kotedia, K1
Urano, M1
Koutcher, JA1
Ling, CC1
Li, GC1
Le Pivert, PJ1
Morrison, DR2
Haddad, RS2
Renard, M2
Aller, A2
Titus, K2
Doulat, J2
Vaishampayan, UN1
Marur, S1
Heilbrun, LK1
Cher, ML1
Dickow, B1
Smith, DW1
Al Hasan, SA1
Eliason, J1
Fung, AS1
Wu, L1
Tannock, IF1
Waller, EK1
Barlett, N1
Chen, CH1
Mujic, V1
Sussman, H1
Toepker, S1
Grenier, K1
Halldén, G1
Mishra, PK1
Gulbake, A1
Jain, A1
Vyas, SP1
Jain, SK1
Cavarretta, IT1
Altanerova, V1
Matuskova, M1
Kucerova, L1
Culig, Z1
Altaner, C1
Njiaju, UO1
Truica, CI1
Rousseau, F1
Retornaz, F1
Joly, F1
Esterni, B1
Abadie-Lacourtoisie, S1
Fargeot, P3
Luporsi, E1
Servent, V1
Laguerre, B1
Brain, E1
Geneve, J1
Wang, BD1
Kline, CL1
Pastor, DM1
Olson, TL1
Frank, B1
Luu, T1
Sharma, AK1
Robertson, G1
Weirauch, MT1
Patierno, SR1
Stuart, JM1
Irby, RB1
Lee, NH1
Walter, B1
Rogenhofer, S1
Vogelhuber, M1
Berand, A1
Wieland, WF1
Andreesen, R1
Reichle, A2
Gasent Blesa, JM1
Giner Marco, V1
Giner-Bosch, V1
Cerezuela Fuentes, P1
Alberola Candel, V1
Saito, N1
Suzuki, T1
Sugito, M1
Ito, M1
Kobayashi, A1
Nishizawa, Y2
Minagawa, N1
Watanabe, K1
Takahashi, S1
Kato, K1
Nakamura, K1
Nakano, R1
Kubota, K1
Hamada, H2
Kawabata, R2
Oie, S2
Oka, T2
Takahashi, M2
Kanayama, H2
Itoh, K2
Hasegawa, M1
Miyajima, A1
Kosaka, T1
Yasumizu, Y1
Tanaka, N1
Maeda, T1
Shirotake, S1
Ide, H1
Kikuchi, E1
Oya, M1
Paumier, A1
Le Péchoux, C1
Nishihara, C1
Senanayake, TH1
Warren, G1
Vinogradov, SV1
Simon, M1
Bioulac-Sage, P1
Trillaud, H1
Blanc, JF1
Ben-Josef, E1
Lawrence, TS1
Meng, LJ1
Fan, WF1
Pu, XL1
Liu, FY1
Yang, M1
Zhou, Z1
He, S1
Fan, T1
Jin, Y1
Chen, C1
Zhang, ZR1
Samuel, T1
Fadlalla, K1
Mosley, L1
Katkoori, V1
Turner, T1
Manne, U1
Roldán, AM1
Núñez, NF1
Grande, E1
García, AÁ1
Antón-Aparicio, LM1
Nagashima, T1
Niiro, M1
Hirayama, K1
Date, S1
Okihara, K2
Mukaisho, K1
Yi, BR1
Hwang, KA1
Kim, YB1
Kim, SU1
Choi, KC1
Corban-Wilhelm, H2
Hull, WE1
Becker, G2
Bauder-Wüst, U2
Greulich, D2
Debus, J2
Mizutani, Y2
Kamoi, K1
Ukimura, O1
Kawauchi, A2
Miki, T2
Yoshimura, I1
Ikegami, S2
Suzuki, S1
Tadakuma, T1
Hayakawa, M1
Bex, A2
Otto, T2
Lümmen, G1
Rübben, H2
Kato, H1
Koshida, K2
Yokoyama, K1
Mizokami, A2
Namiki, M2
Finkelstein, MP1
Aynehchi, S1
Samadi, AA1
Drinis, S1
Choudhury, MS1
Tazaki, H1
Konno, S1
Miyagi, T1
Hori, O1
Konaka, H1
Katoh, H1
Kitagawa, Y1
Egawa, M1
Ogawa, S1
Yu, D1
Agrawal, S1
Zhang, R1
El-Rayes, BF1
Black, CA1
Ensley, JF1
Zimmermann, A1
Walt, H1
Haller, U1
Baas, P1
Klein, SD1
Droz, JP3
Muracciole, X1
Mottet, N1
Ould Kaci, M1
Vannetzel, JM1
Albin, N1
Culine, S1
Rodier, JM1
Misset, JL1
Mackenzie, S1
Cvitkovic, E1
Benoit, G1
Lu, S1
Chen, GL1
Ren, C1
Kwabi-Addo, B1
Epner, DE1
Jenkins, DE1
Oei, Y1
Hornig, YS1
Yu, SF1
Dusich, J1
Purchio, T1
Contag, PR1
Morant, R1
Bernhard, J1
Dietrich, D1
Gillessen, S1
Bonomo, M1
Borner, M1
Bauer, J1
Cerny, T1
Rochlitz, C1
Wernli, M1
Gschwend, A1
Hanselmann, S1
Hering, F1
Schmid, HP1
Le Pivert, P1
Baust, JG3
Gage, AA1
Clarke, D1
Baust, JM3
Van Buskirk, R1
Clarke, DM2
Van Buskirk, RG2
Birtle, AJ1
Newby, JC1
Harland, SJ3
Mazeron, JJ1
Nilsson, S1
Strang, P1
Ginman, C1
Zimmermann, R1
Edgren, M1
Nordström, B1
Ryberg, M1
Kälkner, KM1
Westlin, JE1
Spicer, J1
Plunkett, T1
Somaiah, N1
Chan, S1
Kendall, A1
Bolunwu, N1
Pandha, H1
Nomura, T1
Yamasaki, M1
Nomura, Y1
Mimata, H1
Boucher, PD1
Im, MM1
Freytag, SO1
Shewach, DS1
Rodney, A1
Dieringer, P1
Mathew, P1
Jonasch, E1
Tannir, N1
Pagliaro, LC1
Swanson, GP1
Faulkner, J1
Smalley, SR2
Noble, MJ1
Stephens, RL2
O'Rourke, TJ1
Weiss, GR1
Quick, DP1
Thompson, IM1
Crawford, ED4
Ferrero, JM1
Chamorey, E1
Oudard, S1
Dides, S1
Lesbats, G1
Cavaglione, G1
Nouyrigat, P1
Foa, C1
Kaphan, R1
Vogt, T1
Coras, B1
Hafner, C1
Landthaler, M1
Kolodziej, M1
Neubauer, MA1
Rousey, SR1
Pluenneke, RE1
Perrine, G1
Mull, S1
Boehm, KA1
Ilegbodu, D1
Asmar, L1
Li, Y1
Shiraishi, T1
Mikami, K1
Takaha, N1
Sakai, T1
Mistry, SJ1
Atweh, GF1
Burkitt, M1
Magee, C1
O'Connor, D1
Campbell, F1
Cornford, P1
Greenhalf, W1
Rajeshkumar, NV1
Matwyshyn, G1
Gulati, A1
Munoz, F1
Franco, P1
Ciammella, P1
Clerico, M1
Giudici, M1
Filippi, AR1
Ricardi, U1
Mizukami, H1
Yoshizawa, Y1
Sasaya, S1
Nemoto, H1
Maezawa, K1
Sanada, Y1
Hung, H1
Sanghera, P1
Ho, K1
Muscroft, T1
Hartley, A1
Friedman, J1
Dunn, RL1
Wood, D1
Vaishampayan, U1
Wu, A1
Bradley, D1
Montie, J1
Sarkar, FH1
Shah, RB1
Hussain, M1
Yang, JL1
Qu, XJ1
Yu, Y1
Kohn, EC1
Friedlander, ML1
Takeuchi, H2
Harada, T1
Ohmura, H1
Nishizawa, O1
Tsuchida, S1
Heim, ME1
Eberwein, S1
Georgi, M1
Oberfield, RA1
deKernion, JB2
Lindner, A1
DeWys, WD2
Begg, CB1
Brodovsky, H1
Creech, R1
Khandekar, J1
Nagel, R1
Leistenschneider, W1
Könyves, I1
Müntzing, J1
Rozencweig, M1
Murphy, GP16
Slack, NH3
Mittelman, A3
Citrin, DL1
Elson, P1
Faul, P1
Altwein, JE1
Schmidt, JD9
Burk, K3
Gropp, C2
Rodeck, G1
Logothetis, CJ3
Samuels, ML2
von Eschenbach, AC2
Trindade, A2
Ogden, S1
Grant, C1
Johnson, DE9
Yoshida, K2
Negishi, T2
Kobayashi, N1
Saito, T1
Owada, F1
Ajima, J1
Satake, I1
Tari, K1
Scott, WW8
Gibbons, R1
Prout, GR7
Loening, S2
Soloway, M1
Pontes, JE2
Eisenkraft, S1
Huben, RP2
Babaian, RJ1
Hsu, SD1
Kasimis, BS2
Moran, EM2
Miller, JB2
Forbes, KA2
Kaneshiro, CA2
Poblet, MT1
Williams, JL1
Servadio, C5
Mukamel, E4
Lurie, H1
Nissenkorn, I2
Beckley, S2
Wajsman, Z3
Slack, N1
Torti, FM1
Carter, SK2
Herr, HW1
Muss, HB3
Howard, V1
Richards, F2
White, DR1
Jackson, DV1
Cooper, MR1
Stuart, JJ1
Resnick, MI1
Brodkin, R1
Spurr, CL1
Drago, JR9
Worgul, TJ2
Gallagher, C1
Maeso, E1
Pontes, E1
Murphy, G2
Smalley, RV1
Bartolucci, AA1
Hemstreet, G1
Hester, M1
Goldman, LB5
Gershwin, ME7
Hrushesky, WJ3
Goldman, L1
Jones, MA1
Williams, G1
Shinohara, N2
Harabayashi, T1
Matsuda, H1
Nounaka, O1
Nonomura, K1
Koyanagi, T2
Nagomori, S1
Ohmuro, H2
Matsumara, K1
Demura, T2
Neubauer, BL1
Best, KL1
Counts, DF1
Goode, RL1
Hoover, DM1
Jones, CD1
Sarosdy, MF1
Shaar, CJ1
Tanzer, LR1
Merriman, RL1
Breul, J2
Jakse, G2
Hartung, R2
Dreicer, R2
Forest, PK2
Williams, RD1
Kuriyama, M4
Takeuchi, T4
Takahashi, Y4
Takeda, A1
Ishihara, S1
Ozeki, S1
Ueno, K1
Taniguchi, M1
Yamamoto, N4
Nagatani, Y1
Daliani, DD1
Eisenberg, PD1
Weems, J1
Lord, R1
Fueger, R1
Yagoda, A2
Petrylak, D1
Yamaoka, M1
Yamamoto, T1
Ikeyama, S1
Sudo, K1
Fujita, T1
Lopez Lopez, R1
van Rijswijk, RE1
Wagstaff, J1
Pinedo, HM1
Peters, GJ1
Huan, SD1
Aitken, SE1
Stewart, DJ1
Sakai, H1
Minami, Y1
Kanetake, H1
Saito, Y1
Lokich, J1
Fuhrman, GM1
Ota, DM1
Blumenstein, B1
Saiers, JH2
Rivkin, SE2
Coltman, CA1
Kuzel, TM1
Tallman, MS1
Shevrin, D1
Braud, E1
Kilton, L1
Johnson, P1
Kozlowski, J1
Vogelzang, NJ1
Blough, R1
Benson, AB1
Wozniak, AJ1
Blumenstein, BA1
Boileau, M1
Fletcher, WS1
Atkins, JN2
Case, LD1
Grote, T1
McFarland, J1
Glazier, DB1
Heaney, JA1
Amdur, RJ1
Schned, AR1
Harris, R1
Fukui, I4
Ernstoff, MS1
See, WA1
Wheeler, JA1
Chao, D2
von Schlippe, M1
Forster, G1
Lampel, A1
Rohani, A1
Otsuka, A1
Ono, S1
Hata, M1
Ota, N1
Roigas, J1
Wallen, ES1
Loening, SA1
Moseley, PL1
Yee, LK1
Chu, E1
Pan, BC1
Chu, SH1
Chen, TM1
Lipsky, MH1
Chu, MY1
Calabresi, P1
Berlin, JD1
Propert, KJ1
Trump, D1
Wilding, G1
Hudes, G1
Glick, J1
Burch, P1
Keller, A1
Loehrer, P1
Toyoda, K1
Kashiwagi, A1
Nagamori, S1
Ohzono, S1
Deguchi, T2
Yoh, M2
Yasuda, M2
Nakano, M2
Kawada, Y3
Shinoda, I3
Michael, M1
Moore, MJ1
Kitsukawa, S1
Kinn, T1
Yoshida, T1
Yonese, J1
Izutami, T1
Ishikawa, Y1
Kim, CJ1
Kushima, R1
Okada, Y1
Seto, A1
Yang, CC1
Hsu, CP1
Yang, SD1
Marshall, ME1
Wolf, M1
O'Rourke, M2
Barnett, TC1
Song, S1
Wientjes, MG1
Gan, Y1
Au, JL1
Pan, CC1
Chiang, H1
Chang, YH1
Epstein, JI1
Akaza, H2
Aiba, K1
Isonishi, S1
Ogawa, O1
Shibuya, M1
Sone, S1
Tsuruo, T1
Noguchi, S1
Hinotsu, S1
Kono, S1
Mikami, O1
Blackledge, G1
Vose, B1
Stribling, D1
Wullich, B1
Endris, V1
Rembrink, K1
Stöckle, M1
Siu, W1
Wren, SM1
King, C1
Terris, MK1
Recchia, F1
Sica, G1
De Filippis, S1
Rosselli, M1
Pompili, PL1
Rea, S1
Reimer, CL1
Agata, N1
Tammam, JG1
Bamberg, M1
Dickerson, WM1
Kamphaus, GD1
Rook, SL1
Milhollen, M1
Fram, R1
Kalluri, R1
Kufe, D1
Kharbanda, S1
Fox, RM2
Woods, RL2
Tattersall, MH1
Brodie, GM1
Maurer, RE4
Wasserman, TH1
Saroff, J4
Joiner, JR2
Gibbons, RP6
Merrin, CE2
Alyea, EP1
Dees, JE1
Glenn, JF1
Chlebowski, RT1
Hestorff, R1
Sardoff, L1
Weiner, J1
Bateman, JR1
Eckels, DD2
Lachand, AT1
Garcia-Giralt, E2
Auvert, J1
Juraschek, F1
Mennecier, P1
Pallangie, T1
Moustafa, T1
Eckels, D1
Palmer, JM1
Soloway, MS3
Shippel, RM1
Ikard, M1
Buell, GV1
Saiki, JH1
Bergreen, PW1
Block, NL1
Camuzzi, F1
Stover, B1
Claflin, A1
Troner, M1
Politano, VA1
Nevin, JE4
Hoffman, AA1
Staquet, M1
Younus, S1
Soterakis, J1
Sossi, AJ1
Chawla, SK1
LoPresti, PA1
Ogaard, S1
Jensen, TS1
Kane, RD2
Stocks, LH1
Paulson, DF4
Tejada, F1
Eisenberger, MA1
Broder, LA1
Cohen, MH1
Simon, R1
Reuter, HJ1
Collier, D1
Mickey, DD3
Eagan, RT1
Hahn, RG2
Myers, RP1
Schmidt, JE1
Merrin, C1
Etra, W1
Baumgartner, G1
Fosså, SD1
Miller, A1
Melnick, I3
Baggerly, JT3
Landes, R2
Easley, CA2
Singh, D1
Doroshow, JH1
Leong, L1
Margolin, K1
Akman, S1
Raschko, J1
Somlo, G1
Morgan, R1
Harrison, J1
Cho, J1
Nussbaum, B1
Laurie, JA1
Therneau, TM1
Patel, SR1
Mailliard, JA1
Windschitl, HE1
Twito, DI1
Morton, RF1
Krook, JE1
Ohmori, H1
Matsumura, Y1
Ochi, J2
Kobashi, K1
Akebi, N1
Saika, T1
Nanba, K2
Tanahashi, T2
Josen, T1
Nasu, Y1
Ban, Y1
Ito, Y1
Maeda, S1
Tada, K1
Case, D1
Brockschmidt, J1
Schnell, FM1
Grote, TH1
West, JH1
Anthony, S1
Stanley, V1
Kimler, BF1
Evans, RG1
Hansen, R1
Moynihan, T1
Beatty, P1
Quebbeman, E1
Libnoch, J1
Schulte, W1
Anderson, T1
Tunn, UW1
Goldschmidt, AJ1
Peter, K1
Becker, M1
Goya, N2
Yanagisawa, H1
Nakamura, R2
Toma, H2
Yoshimoto, J1
Saegusa, M1
Hara, M1
Akagi, T1
Obama, T1
Tsushima, T1
Ozaki, Y1
Hickey, D1
Cant, J1
Isurugi, K1
Oishi, Y1
Kitajima, K1
Sawamura, Y1
Baba, S1
Otani, M1
Harada, M1
Gunji, A1
Okada, K1
Kanamaru, H1
Yoshiki, T1
Hashimura, T1
Nishimura, K1
Hida, S1
Nishio, Y1
Oishi, K1
Yoshida, O1
Yamauchi, T1
Carvalho, L2
Foulkes, K2
Apple, JS1
Baber, C1
Putman, CE1
Lupera, H1
Piot, G2
Lapleige, P1
Theodore, C1
Takeuchi, S2
Higashi, Y2
Andoh, M1
Kihara, K2
Kitahara, S2
Horiuchi, S1
Oshima, H2
Portnoĭ, AS1
Hofmann, W1
Langkopf, B1
Manni, A2
Bartholomew, M1
Caplan, R1
Boucher, A1
Santen, R1
Lipton, A2
Harvey, H2
Simmonds, M2
White-Hershey, D1
Gordon, R2
Hosoda, K1
Kawai, T1
Becher, R1
Kurschel, E1
Wandl, U1
Kloke, O1
Scheulen, M1
Weinhardt, O1
Höffken, K1
Niederle, N1
Bergner, S1
Kobayashi, H1
Sahashi, M1
Obata, K1
Sropp, C1
Schultze-Seemann, W1
de Riese, W2
Onitsuka, S1
Nakazawa, H1
Priore, RL1
Scardino, PT1
Priore, R1
Graham, SD1
Walker, A1
Cox, EB1
Laszlo, J1
Berry, WR1
Smith, JB2
Ghayad, PY2
Dhabuwala, CB2
Drelichman, A2
Pierce, JM2
Laplaige, P1
Moran-Ribon, A1
Savion, M1
Santen, RJ1
Boucher, AE1
Rohner, T1
Drago, J1
Wettlaufer, J1
Palangie, T1
Dorval, T1
Jouve, M1
Pouillart, P1
Metter, GE1
Page, JP1
Levi, JA1
Tattersall, MN1
Coates, AS1
Löbenau, S1
Pavone-Macaluso, M2
Basso, A1
Estevez, J1
Li, MC1
Kanwal, G1
Kim, RH1
Armstrong, JG1
Furnari, S1
Veroux, G1
Mattea, E1
Mayr, AC1
Nagel, GA1
Obrecht, JP1
Catalona, WJ2
Hoffman, A1
Landes, RR1
Easley, C1
Greene, LF1
Mulcahy, JJ1
Warren, MM1
Dockerty, MB1
Chauvin, HF1
Boileau, G1
Piro, AJ1
Lahiri, SR1
Hall, TC1
Wilson, CB1
Winternitz, WW1
Rush, BF1
Walton, KN1
Maddy, JA1
Belitsky, P1
Elhilali, MM1
Oliver, JA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine[NCT00006023]Phase 20 participants Interventional2000-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

14 reviews available for fluorouracil and Prostatic Neoplasms

ArticleYear
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2009, Volume: 14 Suppl 1

    Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy

2009
FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Fluorouracil; Humans;

2012
Chemotherapy of hormonally unresponsive prostatic carcinoma.
    The Urologic clinics of North America, 1984, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla

1984
Chemotherapy principles in the treatment of prostatic cancer.
    The Prostate, 1984, Volume: 5, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Castration; Cisplatin; Cyclopho

1984
[Advanced prostatic cancer: therapeutic modalities].
    Deutsche medizinische Wochenschrift (1946), 1984, Dec-21, Volume: 109, Issue:51-52

    Topics: Acid Phosphatase; Antineoplastic Agents; Bromocriptine; Castration; Combined Modality Therapy; Cypro

1984
Cytotoxic agents effective in prostate cancer.
    Seminars in urology, 1983, Volume: 1, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Fluorourac

1983
The chemotherapy of prostatic adenocarcinoma.
    Annals of internal medicine, 1980, Volume: 92, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop

1980
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.
    Cancer, 1993, Feb-01, Volume: 71, Issue:3 Suppl

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Cisplatin; Clinical Trials as Topic;

1993
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1998, Volume: 89, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb

1998
An aggressive approach to prostatic cancer.
    The Journal of urology, 1977, Volume: 118, Issue:1 Pt 2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Castration; Cortisone; Cyclophosphamide; Diethylstilbes

1977
Chemotherapy of prostatic cancer.
    The Urologic clinics of North America, 1975, Volume: 2, Issue:1

    Topics: Aged; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bromoc

1975
[Chemotherapy of prostatic cancer].
    Voprosy onkologii, 1985, Volume: 31, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide;

1985
Genitourinary-tract problems of the aged male.
    Journal of the American Geriatrics Society, 1974, Volume: 22, Issue:8

    Topics: Adenocarcinoma; Age Factors; Aged; Cyclophosphamide; Cyproterone; Diethylstilbestrol; Fluorouracil;

1974
Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
    Cancer, 1973, Volume: 32, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Aniline Compounds; Bone Neoplasms; Cyclophosphamide; Evaluation St

1973

Trials

69 trials available for fluorouracil and Prostatic Neoplasms

ArticleYear
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:9

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Eti

2009
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
    The Journal of urology, 2009, Volume: 182, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence In

2009
Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
    Critical reviews in oncology/hematology, 2010, Volume: 76, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi

2010
Modular therapy approach in metastatic castration-refractory prostate cancer.
    World journal of urology, 2010, Volume: 28, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamet

2010
Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.
    American journal of clinical oncology, 2011, Volume: 34, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine

2011
Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
    Urologia internationalis, 2002, Volume: 69, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Drug

2002
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Disease-Free Survival; Dose-Response Relationship, Dru

2003
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
    British journal of cancer, 2004, Apr-05, Volume: 90, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neop

2004
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
    Journal of pain and symptom management, 2005, Volume: 29, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Epirubici

2005
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
    Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Capecitabine; Deoxycytidine; Drug Resistan

2005
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
    Cancer, 2006, May-15, Volume: 106, Issue:10

    Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug

2006
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Cancer, 2006, Aug-15, Volume: 107, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2006
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
    Clinical genitourinary cancer, 2006, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2006
[Effectiveness of 5-fluorouracil combined with hormones in low dose as a basal treatment for prostatic carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 1984, Volume: 30, Issue:11

    Topics: Aged; Allylestrenol; Combined Modality Therapy; Drug Therapy, Combination; Estrenes; Fluorouracil; H

1984
Chemotherapy of hormonally unresponsive prostatic carcinoma.
    The Urologic clinics of North America, 1984, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla

1984
A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.
    The Prostate, 1983, Volume: 4, Issue:1

    Topics: Acid Phosphatase; Adenocarcinoma; Clinical Trials as Topic; Doxorubicin; Fluorouracil; Humans; Male;

1983
[Cytostatic therapy of prostatic carcinoma. Current status and personal results].
    Der Urologe. Ausg. A, 1983, Volume: 22 Suppl

    Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Drug Thera

1983
Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Seminars in oncology, 1983, Volume: 10, Issue:3 Suppl 3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Cisplatin; Clinical Tria

1983
Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
    Cancer, 1984, Jul-01, Volume: 54, Issue:1

    Topics: Acid Phosphatase; Aged; Bone Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Fluo

1984
The chemotherapy of prostatic carcinoma.
    Scandinavian journal of urology and nephrology. Supplementum, 1980, Volume: 55

    Topics: Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Immunity, Innate; Male; Neoplasm Stag

1980
The chemotherapy of prostatic adenocarcinoma.
    Annals of internal medicine, 1980, Volume: 92, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop

1980
Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
    The Journal of urology, 1982, Volume: 127, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; F

1982
Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
    Cancer, 1981, Apr-15, Volume: 47, Issue:8

    Topics: Aged; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Hu

1981
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
    The Journal of urology, 1981, Volume: 125, Issue:2

    Topics: Adenocarcinoma; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug T

1981
[5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1995, Volume: 86, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance,

1995
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
    Urology, 1994, Volume: 44, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admini

1994
Intra-arterial chemotherapy using a reservoir for endocrine-refractory prostate cancer.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35 Suppl

    Topics: Abdominal Muscles; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati

1994
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
    The Journal of urology, 1995, Volume: 153, Issue:5

    Topics: Adenocarcinoma; Aged; Disease Progression; Fluorouracil; Humans; Interferon-alpha; Male; Prospective

1995
5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Leucovorin; Ma

1994
Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35 Suppl

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone

1994
A Phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study.
    Cancer, 1994, Mar-01, Volume: 73, Issue:5

    Topics: Fluorouracil; Humans; Illinois; Infusions, Parenteral; Male; Prostatic Neoplasms

1994
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
    The Journal of urology, 1993, Volume: 150, Issue:2 Pt 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1993
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
    Cancer, 1993, Sep-15, Volume: 72, Issue:6

    Topics: Aged; Fluorouracil; Hormones; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis

1993
Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy P

1993
Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.
    American journal of clinical oncology, 1996, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leucovori

1996
5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study.
    The Journal of urology, 1996, Volume: 155, Issue:2

    Topics: Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C

1996
Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial.
    Cancer, 1996, Mar-01, Volume: 77, Issue:5

    Topics: Aged; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Fluorouracil; Gold Radioisoto

1996
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

1997
5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial.
    European urology, 1997, Volume: 32, Issue:3

    Topics: Aged; Androgens; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Drug Therapy, Combinati

1997
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; H

1998
5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
    The Prostate, 1998, Apr-01, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy

1998
[Intra-arterial chemotherapy via reservoir system for advanced bladder cancer and prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1999, Volume: 45, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin

1999
Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma.
    American journal of clinical oncology, 2001, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembr

2001
[Chemotherapy of advanced prostate cancer].
    Voprosy onkologii, 1977, Volume: 23, Issue:12

    Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Eval

1977
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
    Cancer, 1978, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Digestive System; Dox

1978
The randomized clinical trial: a prerequisite for rational therapy.
    European urology, 1976, Volume: 2, Issue:6

    Topics: Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Double-Blind Method; Doxorubicin; Fe

1976
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea

1977
Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
    Urology, 1976, Volume: 7, Issue:6

    Topics: Aged; Body Weight; Bone Marrow Examination; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Fluor

1976
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    The Journal of urology, 1976, Volume: 116, Issue:2

    Topics: Carcinoma; Cyclophosphamide; Evaluation Studies as Topic; Fluorouracil; Humans; Male; Neoplasm Recur

1976
Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy.
    Urology, 1976, Volume: 8, Issue:3

    Topics: Carcinoma; Cyclophosphamide; Fluorouracil; Humans; Male; Prostatic Neoplasms

1976
Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Cancer treatment reports, 1976, Volume: 60, Issue:1

    Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Male; Middle A

1976
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    Transactions of the American Association of Genito-Urinary Surgeons, 1976, Volume: 68

    Topics: Carcinoma; Cyclophosphamide; Fluorouracil; Humans; Male; Maryland; Prognosis; Prostatic Neoplasms

1976
Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study.
    The Journal of urology, 1975, Volume: 114, Issue:6

    Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Fluorouracil; Humans; Male; Prostatic N

1975
Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
    The Journal of urology, 1976, Volume: 115, Issue:1

    Topics: Adenocarcinoma; Aged; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evalua

1976
Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.
    Journal of cancer research and clinical oncology, 1992, Volume: 119, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Fluorouracil; Humans; Leucovorin

1992
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
    Cancer, 1992, Mar-15, Volume: 69, Issue:6

    Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo

1992
High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
    American journal of clinical oncology, 1991, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Evaluation; Fluorouracil; Humans; Infusions, In

1991
Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer.
    Urology, 1991, Volume: 37, Issue:4

    Topics: Drug Evaluation; Fluorouracil; Humans; Infusions, Intravenous; Male; Prostatic Neoplasms

1991
Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation.
    Urology, 1988, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamid

1988
A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
    Japanese journal of clinical oncology, 1988, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Diethylstilbestr

1988
Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:9

    Topics: Acid Phosphatase; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Clinical

1988
[A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report)].
    Nihon Gan Chiryo Gakkai shi, 1988, Oct-20, Volume: 23, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation;

1988
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect

1988
Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Urology, 1988, Volume: 32, Issue:1

    Topics: Acid Phosphatase; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

1988
Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
    Urology, 1986, Volume: 28, Issue:1

    Topics: Blood Platelets; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Estramus

1986
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
    Urology, 1986, Volume: 28, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp

1986
Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
    Journal of steroid biochemistry, 1987, Volume: 27, Issue:1-3

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Combined Modality

1987
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin;

1985
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do

1985

Other Studies

199 other studies available for fluorouracil and Prostatic Neoplasms

ArticleYear
Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer.
    Bioorganic & medicinal chemistry letters, 2004, Oct-04, Volume: 14, Issue:19

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Humans; Male; Phospholipids

2004
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer.
    Bioorganic & medicinal chemistry letters, 2004, Nov-01, Volume: 14, Issue:21

    Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Male; Pro

2004
Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer.
    Journal of medicinal chemistry, 2005, Apr-07, Volume: 48, Issue:7

    Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans

2005
SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: a novel class of cytotoxic agents for prostate cancer.
    Bioorganic & medicinal chemistry letters, 2005, Sep-15, Volume: 15, Issue:18

    Topics: Amides; Antineoplastic Agents; Carboxylic Acids; Cell Line; Cell Proliferation; Humans; Inhibitory C

2005
Novel 2,4,5-trisubstituted oxazole derivatives: synthesis and antiproliferative activity.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Hu

2009
Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:8

    Topics: 4-Butyrolactone; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Ehrlich Tumor; Cell C

2011
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Fe

2012
Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.
    European journal of medicinal chemistry, 2013, Volume: 65

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge

2013
Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents.
    Bioorganic & medicinal chemistry letters, 2016, 06-15, Volume: 26, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell

2016
Antiproliferative and Anti-inflammatory Withanolides from Physalis angulata.
    Journal of natural products, 2016, 06-24, Volume: 79, Issue:6

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Crystallography, X-Ray; Drug Screening

2016
Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines.
    Bioorganic & medicinal chemistry letters, 2016, 09-01, Volume: 26, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle Checkpoin

2016
Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs.
    Bioorganic & medicinal chemistry letters, 2022, 05-15, Volume: 64

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship,

2022
Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.
    Archiv der Pharmazie, 2022, Volume: 355, Issue:1

    Topics: Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Hum

2022
Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
    International journal of molecular sciences, 2021, Nov-05, Volume: 22, Issue:21

    Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell

2021
Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells.
    ChemMedChem, 2023, 04-17, Volume: 18, Issue:8

    Topics: Cell Line; Fluorouracil; Heme Oxygenase-1; Humans; Imidazoles; Male; Prodrugs; Prostate; Prostatic N

2023
[PRIMARY SQUAMOUS CELL CARCINOMA OF THE PROSTATE: A CASE REPORT].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2019, Volume: 110, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura

2019
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
    Bulletin du cancer, 2021, Volume: 108, Issue:3

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases

2021
Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.
    PloS one, 2017, Volume: 12, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Clopidogrel; Fluorouracil; Humans; Male; Mice; Neo

2017
Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient-a case report.
    Mutation research, 2013, Aug-30, Volume: 756, Issue:1-2

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Chromosome Aberratio

2013
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2013, Nov-15, Volume: 20, Issue:14

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Ce

2013
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
    International journal of radiation oncology, biology, physics, 2013, Dec-01, Volume: 87, Issue:5

    Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis

2013
shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.
    International urology and nephrology, 2014, Volume: 46, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cel

2014
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
    International journal of radiation oncology, biology, physics, 2014, Sep-01, Volume: 90, Issue:1

    Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Evaluation of the cytotoxic effects of PLGA coated iron oxide nanoparticles as a carrier of 5- fluorouracil and mega-voltage X-ray radiation in DU145 prostate cancer cell line.
    IEEE transactions on nanobioscience, 2014, Volume: 13, Issue:4

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Chemoradiotherapy; Coated Materials, B

2014
Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
    ACS applied materials & interfaces, 2015, Apr-01, Volume: 7, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems;

2015
Prostate Cancer Heterogeneous High-Metastatic Multi-Organ-Colonizing Chemo-Resistant Variants Selected by Serial Metastatic Passage in Nude Mice Are Highly Enriched for Multinucleate Giant Cells.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubi

2015
Reply to I. Gounaris and M. Hall et al.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 05-01, Volume: 35, Issue:13

    Topics: Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Prostatic Neoplasms; Rectal Neoplasms

2017
[Bystander effect of target-regulated uracil phosphoribosyltransferase/5-fluorouracil suicide gene system on prostate cancer cell].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2008, Volume: 39, Issue:3

    Topics: Antimetabolites, Antineoplastic; Bystander Effect; Cell Line, Tumor; Cell Survival; Fluorouracil; Ge

2008
Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
    Prostate cancer and prostatic diseases, 2009, Volume: 12, Issue:2

    Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Enhancer Elements, Genetic; Escherichia

2009
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer.
    Oncology reports, 2009, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluorouracil;

2009
Effective combined chemotherapy for prostatic ductal adenocarcinoma: continuous venous infusion of 5-fluorouracil and low-dose consecutive cisplatin.
    BJU international, 2003, Volume: 92 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal; Cisplatin; Fluorouracil; Humans;

2003
E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells.
    Cancer research, 2009, Mar-15, Volume: 69, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Ea

2009
Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009, Volume: 92, Issue:3

    Topics: Animals; Blotting, Western; Bystander Effect; Cell Line, Tumor; Coculture Techniques; Cytosine Deami

2009
Percutaneous tumor ablation: microencapsulated echo-guided interstitial chemotherapy combined with cryosurgery increases necrosis in prostate cancer.
    Technology in cancer research & treatment, 2009, Volume: 8, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cryosurgery;

2009
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-01, Volume: 15, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tu

2009
Variations in the content of CD34+ cells in the peripheral blood of cancer patients receiving out-patient chemotherapy.
    Cytotherapy, 1999, Volume: 1, Issue:1

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

1999
Targeted delivery of an anti-cancer agent via steroid coupled liposomes.
    Drug delivery, 2009, Volume: 16, Issue:8

    Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Compounding; Drug Delivery Systems; Fluorouracil

2009
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2010, Volume: 18, Issue:1

    Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Male; Mesenchymal

2010
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
    Clinical breast cancer, 2010, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Ma

2010
Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network.
    Molecular cancer, 2010, Apr-30, Volume: 9

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Chromatin Immuno

2010
Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract.
    Journal of surgical oncology, 2010, Dec-01, Volume: 102, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Feasibility

2010
Neural cell adhesion molecule 2 as a target molecule for prostate and breast cancer gene therapy.
    Cancer science, 2011, Volume: 102, Issue:4

    Topics: Adenoviridae; Amino Acid Sequence; Animals; Animals, Newborn; Antibodies, Monoclonal; Antimetabolite

2011
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    International journal of oncology, 2011, Volume: 38, Issue:3

    Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug E

2011
Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
    International journal of cancer, 2012, Jan-15, Volume: 130, Issue:2

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Com

2012
Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
    International journal of oncology, 2011, Volume: 38, Issue:6

    Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell

2011
[Comments on "Normal tissue tolerance to external beam radiotherapy: Small bowel" by Martin et al. (Cancer Radiother 14:350-3)].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2011, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Genital Neoplasms, Female; H

2011
[Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].
    Hinyokika kiyo. Acta urologica Japonica, 2011, Volume: 57, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents,

2011
Quantitative analysis of the enzymes associated with 5-fluorouracil metabolism in prostate cancer biopsies.
    Methods in molecular biology (Clifton, N.J.), 2011, Volume: 755

    Topics: Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression; Humans; Lasers; Male; Microdissec

2011
Novel anticancer polymeric conjugates of activated nucleoside analogues.
    Bioconjugate chemistry, 2011, Oct-19, Volume: 22, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Female; Fluorouracil; Human

2011
Radiotherapy: the importance of local control in pancreatic cancer.
    Nature reviews. Clinical oncology, 2011, Nov-29, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; M

2011
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:2

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosp

2012
Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates.
    Biomaterials, 2012, Volume: 33, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; En

2012
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
    Anticancer research, 2012, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein;

2012
A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2012
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2012, Volume: 58, Issue:8

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplasti

2012
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
    International journal of molecular sciences, 2012, Sep-28, Volume: 13, Issue:10

    Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell S

2012
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
    Gene therapy, 2002, Volume: 9, Issue:23

    Topics: Animals; Antimetabolites; Bystander Effect; Cell Survival; Cytosine Deaminase; Disease Models, Anima

2002
Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
    The Journal of urology, 2002, Volume: 168, Issue:6

    Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzenesulfon

2002
Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
    The Journal of urology, 2002, Volume: 168, Issue:6

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cytosine Deaminase; Enhancer Elements, Genet

2002
Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study.
    International journal of urology : official journal of the Japanese Urological Association, 2002, Volume: 9, Issue:10

    Topics: Animals; Antimetabolites; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil;

2002
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
    Journal of alternative and complementary medicine (New York, N.Y.), 2002, Volume: 8, Issue:5

    Topics: Agaricales; Androgens; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto

2002
Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system.
    The journal of gene medicine, 2003, Volume: 5, Issue:1

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line; Cytosine Deaminase; Fluorouracil;

2003
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    The Prostate, 2003, Feb-15, Volume: 54, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin

2003
Hormone-refractory prostate cancer responding to capecitabine.
    Urology, 2003, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Agents,

2003
Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:2

    Topics: Apoptosis; Breast Neoplasms; Carcinoma, Basal Cell; Floxuridine; Fluorouracil; Humans; Male; Mesopor

2003
Methionine restriction selectively targets thymidylate synthase in prostate cancer cells.
    Biochemical pharmacology, 2003, Sep-01, Volume: 66, Issue:5

    Topics: Antimetabolites, Antineoplastic; Cell Division; Fluorouracil; Folic Acid; Humans; Male; Methionine;

2003
Cytosine deaminase versus thymidine kinase: a comparison of the antitumor activity.
    Clinical and experimental medicine, 2003, Volume: 3, Issue:3

    Topics: Animals; Antiviral Agents; Cytosine Deaminase; Escherichia coli; Fluorouracil; Ganciclovir; Genetic

2003
Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.
    Clinical & experimental metastasis, 2003, Volume: 20, Issue:8

    Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Image Interpretation, Computer-A

2003
Ultrasound guided combined cryoablation and microencapsulated 5-Fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging.
    Technology in cancer research & treatment, 2004, Volume: 3, Issue:2

    Topics: Animals; Combined Modality Therapy; Cryosurgery; Diagnostic Imaging; Fluorouracil; Genetic Engineeri

2004
Cryosurgery--a putative approach to molecular-based optimization.
    Cryobiology, 2004, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Cell S

2004
Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement.
    Cryobiology, 2004, Volume: 49, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Death; Cell Line, Tumor; Chemothe

2004
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E

2004
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2005, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo

2005
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Methods in molecular medicine, 2005, Volume: 111

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms;

2005
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
    Oncology reports, 2005, Volume: 14, Issue:4

    Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Pro

2005
A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy.
    Cancer research, 2006, Mar-15, Volume: 66, Issue:6

    Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytosine Deaminase;

2006
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
    The Journal of urology, 2006, Volume: 176, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Huma

2006
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
    The Lancet. Oncology, 2006, Volume: 7, Issue:8

    Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecit

2006
The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
    BJU international, 2007, Volume: 99, Issue:3

    Topics: Aged; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase

2007
Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:12

    Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Th

2006
Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition.
    Molecular carcinogenesis, 2007, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Apoptotic Protease-Activating Factor 1; Benzoquinones; Cell Line, Tumor; Cell

2007
IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats.
    The Prostate, 2007, May-15, Volume: 67, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biolog

2007
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.
    Radiation oncology (London, England), 2007, Apr-03, Volume: 2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease

2007
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi

2007
Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis

2007
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
    The British journal of radiology, 2007, Volume: 80, Issue:956

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans

2007
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
    The Journal of urology, 2008, Volume: 179, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel;

2008
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
    International journal of cancer, 2008, Jul-15, Volume: 123, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome

2008
Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract.
    The Journal of urology, 1982, Volume: 128, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Carcinoma, Transitional Cell; Charcoal; Doxorubicin; Female;

1982
Palliative therapy of pelvic tumors by intra-arterial infusion of cytotoxic drugs.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Doxorubicin; Fe

1983
Intra-arterial infusion in tumors of the pelvis.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T

1983
The therapeutic effect of concurrent administration of 5-fluorouracil and allylestrenol or hexestrol in small doses on prostatic carcinoma.
    The Prostate. Supplement, 1981, Volume: 1

    Topics: Aged; Allylestrenol; Drug Therapy, Combination; Estrenes; Fluorouracil; Hexestrol; Humans; Male; Mid

1981
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
    Der Urologe. Ausg. A, 1983, Volume: 22 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1983
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev

1983
[Effects of long-term administration of Tegafur on patients with relapsing advanced carcinoma (stage D) of the prostate].
    Hinyokika kiyo. Acta urologica Japonica, 1983, Volume: 29, Issue:1

    Topics: Aged; Estrogens; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo

1983
Chemotherapy programs of the National Prostatic Cancer Project (NPCP).
    Cancer, 1980, Apr-15, Volume: 45, Issue:7 Suppl

    Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Evaluation; Drug Ther

1980
Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases.
    Urology, 1984, Volume: 23, Issue:6 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Cisplatin; Combined Moda

1984
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
    Urology, 1984, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Doxorubicin; Estro

1984
Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Cancer treatment reports, 1983, Volume: 67, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Male; Middl

1983
Early combined hormonal and chemotherapy for metastatic prostatic carcinoma.
    Urology, 1983, Volume: 21, Issue:5

    Topics: Aged; Bone Neoplasms; Carcinoma; Castration; Cyclophosphamide; Diethylstilbestrol; Fluorouracil; Hum

1983
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
    Cancer treatment reports, 1982, Volume: 66, Issue:1

    Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N

1982
Chemotherapy of hormone-resistant stage D prostatic cancer.
    The Journal of urology, 1980, Volume: 123, Issue:6

    Topics: Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; E

1980
New agents for prostatic carcinoma.
    Urology, 1981, Volume: 17, Issue:4 Suppl

    Topics: Adamantane; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Es

1981
Castration--chemotherapy treatment of prostate cancer model.
    The Journal of surgical research, 1981, Volume: 30, Issue:4

    Topics: Animals; Carmustine; Castration; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Disea

1981
Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
    Urology, 1981, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Estra

1981
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
    Investigative urology, 1981, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy,

1981
Cooperative clinical trials in prostate cancer.
    Progress in clinical and biological research, 1981, Volume: 75B

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Fluorouracil; Hormones; Humans; Male;

1981
Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
    Cancer, 1980, Jul-15, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Ev

1980
Unusual pigmentary changes associated with 5-fluorouracil therapy.
    Cutis, 1980, Volume: 26, Issue:2

    Topics: Fluorouracil; Humans; Male; Middle Aged; Pigmentation Disorders; Prostatic Neoplasms

1980
Evaluation of chemotherapeutic responsiveness in Nb rat prostate cancer model. 5-fluorouracil, methotrexate, cyclophosphamide, and adriamycin.
    Investigative urology, 1980, Volume: 18, Issue:1

    Topics: Animals; Cyclophosphamide; Doxorubicin; Fluorouracil; Male; Methotrexate; Neoplasms, Experimental; P

1980
Early combined hormonal and chemotherapy for metastatic carcinoma of prostate.
    Urology, 1980, Volume: 16, Issue:3

    Topics: Aged; Castration; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Combination; Fluorouracil; Hum

1980
The non-hormone chemotherapy of prostatic cancer.
    British journal of urology, 1980, Volume: 52, Issue:2

    Topics: Bone Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; M

1980
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
    The Prostate, 1995, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis

1995
Biomodulation of 5-Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer.
    Urological research, 1995, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Drug Synergism; Fluorouracil; Humans; Leucovorin; Male; Prostatic Neoplasms;

1995
Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.
    Cancer research, 1993, Nov-01, Volume: 53, Issue:21

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas

1993
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi

1994
Laparoscopic intestinal stomas.
    Diseases of the colon and rectum, 1994, Volume: 37, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy;

1994
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
    European urology, 1997, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

1997
[Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell;

1997
Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells.
    The Prostate, 1998, Feb-15, Volume: 34, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cisplatin; Combined

1998
Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
    Pharmacology, 1998, Volume: 56, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Inter

1998
[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1998
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neop

1998
Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome.
    The Prostate, 2000, Mar-01, Volume: 42, Issue:4

    Topics: Adult; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cisplatin; Dacarbazine;

2000
Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; DNA, Antisense; DNA, Complementary; DN

2000
Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
    Cancer biotherapy & radiopharmaceuticals, 1996, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouraci

1996
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Jul-18, Volume: 97, Issue:15

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic

2000
Tubulocystic clear cell adenocarcinoma arising within the prostate.
    The American journal of surgical pathology, 2000, Volume: 24, Issue:10

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fluor

2000
[Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:11

    Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung;

2000
Comparison of the malignant phenotype and genotype of the human androgen-independent cell line DU 145 and a subline derived from metastasis after orthotopic implantation in nude mice.
    Cancer genetics and cytogenetics, 2001, Jan-15, Volume: 124, Issue:2

    Topics: Androgens; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Chromosome Aberrations; C

2001
External beam radiotherapy for synchronous rectal and prostatic tumors.
    Urology, 2001, Volume: 57, Issue:4

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplas

2001
Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer.
    Cryobiology, 2001, Volume: 42, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Death; Chemotherapy, Adjuvant; Combined Modality Ther

2001
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
    Cancer research, 2002, Feb-01, Volume: 62, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Cou

2002
Allopurinol modulation of high-dose fluorouracil toxicity.
    Lancet (London, England), 1979, Mar-24, Volume: 1, Issue:8117

    Topics: Administration, Oral; Allopurinol; Drug Antagonism; Drug Therapy, Combination; Female; Fluorouracil;

1979
Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostatic adenocarcinoma. Chemotherapy of autonomous tumor, 102 Pr, heterotransplanted into congenitally athymic (nude) mice and syngeneic Nb rats.
    Cancer chemotherapy and pharmacology, 1979, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Animals; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms,

1979
The chemotherapy of urologic cancer.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co

1975
Chemotherapy of advanced prostatic cancer by the National Prostatic Cancer Group.
    Seminars in oncology, 1976, Volume: 3, Issue:2

    Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Fluorouracil; Humans; Male; Procarbazine; Pros

1976
Chemotherapy of advanced prostatic cancer today.
    Progress in clinical and biological research, 1976, Volume: 6

    Topics: Aged; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Estramustine; Fluorourac

1976
Chemotherapy of urogenital cancer.
    Surgery annual, 1976, Volume: 8

    Topics: Adenocarcinoma; Adult; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Hum

1976
Chemotherapy of Nb rat adenocarcinoma of the prostate heterotransplanted into congenitally athymic (nude) mice: report of 5-fluorouracil and cyclophosphamide.
    The Journal of surgical research, 1979, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Animals; Cyclophosphamide; Disease Models, Animal; Fluorouracil; Male; Mice; Mice, N

1979
Sequential polychemotherapy for advanced prostatic carcinoma. A preliminary cooperative study on 30 patients.
    European urology, 1979, Volume: 5, Issue:4

    Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Male; Neoplasm Metas

1979
The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice.
    Cancer, 1979, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Animals; Doxorubicin; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation

1979
Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
    Investigative urology, 1979, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Evaluation Studies as

1979
Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
    The Journal of urology, 1979, Volume: 122, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Drug The

1979
Prostate adenocarcinoma model: Nb rat chemotherapy.
    Surgical forum, 1979, Volume: 30

    Topics: Adenocarcinoma; Animals; Castration; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Doxorub

1979
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
    Urology, 1978, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu

1978
Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
    Transactions of the American Association of Genito-Urinary Surgeons, 1978, Volume: 70

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Dactinomycin; Doxoru

1978
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
    American journal of surgery, 1975, Volume: 130, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc

1975
Hypoglycemia secondary to metastases to the liver. A case report and review of the literature.
    Gastroenterology, 1977, Volume: 72, Issue:2

    Topics: Aged; Cyclophosphamide; Fluorouracil; Humans; Hypoglycemia; Liver Neoplasms; Male; Neoplasm Metastas

1977
[Combination cytostatic chemotherapy of advanced metastatic cancer of the prostate. A preliminary uncontrolled study].
    Ugeskrift for laeger, 1977, Feb-28, Volume: 139, Issue:9

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Diseases; Cyclophosphamide; Dr

1977
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
    The Journal of urology, 1977, Volume: 117, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug The

1977
Letter: Serpentine supravenous fluorouracil hyperpigmentation.
    JAMA, 1976, Jul-12, Volume: 236, Issue:2

    Topics: Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Pigmentation Disorders; Prostatic

1976
[Multifactorial immunological treatment of cancer in urology].
    Helvetica chirurgica acta, 1976, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Cobalt Radioisotopes; Female; Fluorouracil; Humans;

1976
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
    Urology, 1976, Volume: 8, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin;

1976
Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation.
    Cancer treatment reports, 1976, Volume: 60, Issue:5

    Topics: Fluorouracil; Humans; Male; Middle Aged; Pigmentation Disorders; Prostatic Neoplasms

1976
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
    Urology, 1976, Volume: 8, Issue:6

    Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil;

1976
[Treatment of advanced prostatic cancer].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1975, May-10, Volume: 95, Issue:13

    Topics: Adrenalectomy; Aged; Estrogens; Fluorouracil; Humans; Hypophysectomy; Male; Neoplasm Metastasis; Pro

1975
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
    Virginia medical monthly, 1975, Volume: 102, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou

1975
Fifteen years' experience of combined hormone/chemotherapy in metastatic prostate cancer.
    Urology, 1992, Volume: 39, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comb

1992
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru

1991
[Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT].
    Hinyokika kiyo. Acta urologica Japonica, 1991, Volume: 37, Issue:7

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Pr

1991
5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells.
    International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorour

1991
Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
    Progress in clinical and biological research, 1990, Volume: 359

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda

1990
[5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU].
    Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Animals; Fluorouracil; Humans; Linear

1990
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A

1987
[Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro].
    Hinyokika kiyo. Acta urologica Japonica, 1988, Volume: 34, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Line

1988
Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma.
    The Prostate, 1989, Volume: 15, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos

1989
Advanced prostatic carcinoma: pulmonary manifestations.
    Radiology, 1985, Volume: 154, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Fluorouracil; Hum

1985
Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma.
    The Journal of urology, 1989, Volume: 142, Issue:6

    Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P

1989
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
    Oncology, 1989, Volume: 46, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug E

1989
[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1989, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Human

1989
[Chemotherapy of advanced prostate cancer].
    Zeitschrift fur Urologie und Nephrologie, 1986, Volume: 79, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cisplatin; Combined Modality Therapy;

1986
[Study on the concentration of FT-207 and 5-FU in serum and tissues of bladder tumor and prostatic carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6

    Topics: Adult; Aged; Fluorouracil; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Suppositories;

1986
Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly.
    Progress in clinical and biological research, 1987, Volume: 243B

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Fluorouracil; Humans;

1987
Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma.
    The Journal of urology, 1988, Volume: 140, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Combined Modality Therap

1988
Effects of cyclophosphamide alone and scheduled methotrexate-5-fluorouracil combination chemotherapy on transplantable R-3327 prostatic adenocarcinoma in F1 hybrid male rat.
    Urology, 1987, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluoroura

1987
Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.
    Progress in clinical and biological research, 1987, Volume: 243B

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Fluor

1987
The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
    Progress in clinical and biological research, 1987, Volume: 243B

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Diethyl

1987
Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up.
    Urology, 1987, Volume: 30, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1987
[Advanced cancer of the prostate: chemotherapy].
    Bulletin du cancer, 1986, Volume: 73, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; F

1986
The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
    Cancer, 1985, Sep-01, Volume: 56, Issue:5

    Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami

1985
[Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
    Helvetica chirurgica acta, 1985, Volume: 52, Issue:3-4

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac

1985
Chemotherapy of vesical and prostatic tumours.
    British journal of urology, 1971, Volume: 43, Issue:6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cobalt Isotopes; Cystitis; Daunorubic

1971
Proceedings: Cancer of the prostate.
    Cancer, 1973, Volume: 32, Issue:5

    Topics: Amides; Antineoplastic Agents; Arginase; Bleomycin; Busulfan; Carbamates; Chromomycins; Cyclic P-Oxi

1973
Arterial infusion of 5-fluorouracil as a treatment for carcinoma of the prostate.
    The Journal of urology, 1974, Volume: 112, Issue:1

    Topics: Aged; Catheterization; Fluorouracil; Humans; Iliac Artery; Injections, Intra-Arterial; Male; Middle

1974
Prostatic tumor acid phosphatase production. Influence of antineoplastic agents.
    Urology, 1973, Volume: 1, Issue:3

    Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Antineoplastic Agents; Aspartate Aminotransferases; Bl

1973
Current problems in the use of the oncolytic drugs.
    Acta geneticae medicae et gemellologiae, 1968, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac

1968
Cancer chemotherapy in urology.
    Urologia internationalis, 1971, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal

1971
[Cytostatic chemotherapy in carcinomas of prostate and corpus uteri (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1974, Feb-05, Volume: 63, Issue:5

    Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Ma

1974
Host-tumor interactions during 5-fluorouracil therapy for prostatic carcinoma.
    Urology, 1974, Volume: 4, Issue:3

    Topics: Fluorouracil; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Neopl

1974
Effects of chemotherapy for prostatic carcinoma on T lymphocyte levels.
    The Journal of urology, 1974, Volume: 112, Issue:6

    Topics: Administration, Oral; Aged; Animals; Cyclophosphamide; Diethylstilbestrol; Erythrocytes; Fluorouraci

1974
The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of advanced carcinoma of the bladder and prostate. A preliminary report.
    Cancer, 1973, Volume: 31, Issue:1

    Topics: Aged; Carcinoma; Cobalt Isotopes; Dose-Response Relationship, Drug; Dose-Response Relationship, Radi

1973
Primary transitional cell carcinoma of the prostate.
    The Journal of urology, 1973, Volume: 110, Issue:2

    Topics: Aged; Alkaline Phosphatase; Blood Urea Nitrogen; Carcinoma, Transitional Cell; Diethylstilbestrol; F

1973
Proceedings: Rationale and results of primary endocrine therapy in patients with prostatic cancer.
    Cancer, 1973, Volume: 32, Issue:5

    Topics: Androgen Antagonists; Animals; Arginase; Body Weight; Castration; Cyclophosphamide; Cyproterone; Dis

1973
[Trial of combined intermittent chemotherapy in prostatic cancers. Estrogen resistant metastases].
    Journal d'urologie et de nephrologie, 1973, Volume: 79, Issue:12 Pt 2

    Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Therapy, Combination; Estrogens; Fluorouracil; Fol

1973
Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy.
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:5

    Topics: Aged; Breast Neoplasms; Castration; Cerebellar Ataxia; Diagnosis, Differential; Female; Fluorouracil

1971
Cryohypophysectomy: indications, technic, and results.
    International surgery, 1967, Volume: 48, Issue:1

    Topics: Acromegaly; Adenoma, Chromophobe; Adult; Breast Neoplasms; Carcinoma; Castration; Cryosurgery; Cushi

1967
Effect of stilbestrol on the isoenzymes of lactate dehydrogenase in benign and malignant prostatic tissue.
    The Journal of urology, 1970, Volume: 104, Issue:3

    Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Depression, Chemical; Diethylstilbestrol; Est

1970
[Therapy of testicular tumors and prostatic carcinoma].
    Minerva medica, 1971, Apr-07, Volume: 62, Issue:28

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cobalt Isotopes; Estrogens; Fluorouracil; Humans; Male

1971